共 50 条
Treatment approach to connective tissue disease-associated interstitial lung disease
被引:13
|作者:
Wilson, Timothy M.
[1
]
Solomon, Joshua J.
[2
]
Demoruelle, M. Kristen
[1
]
机构:
[1] Univ Colorado Denver, Div Rheumatol, Aurora, CO 80204 USA
[2] Natl Jewish Hlth, Div Pulm Crit Care & Sleep Med, Denver, CO USA
基金:
美国国家卫生研究院;
关键词:
RHEUMATOID-ARTHRITIS;
SYSTEMIC-SCLEROSIS;
DOUBLE-BLIND;
DERMATOMYOSITIS;
MORTALITY;
SURVIVAL;
CYCLOPHOSPHAMIDE;
MANIFESTATIONS;
INTERLEUKIN-6;
TOCILIZUMAB;
D O I:
10.1016/j.coph.2022.102245
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Interstitial lung disease (ILD) is a common manifestation in connective tissue diseases (CTD), such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myositis (IM). ILD is associated with significant morbidity and mortality in nearly all CTD highlighting the critical need for effective treatment strategies in this patient population. In this review, we will summarize the approach to treatment when there is concern for CTD-ILD and highlight recent advancements in therapeutics within various forms of CTD-ILD.
引用
收藏
页数:6
相关论文